CN1418678A - 一种治疗心脑血管疾病的药物组合物及其制备方法 - Google Patents
一种治疗心脑血管疾病的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1418678A CN1418678A CN 02153312 CN02153312A CN1418678A CN 1418678 A CN1418678 A CN 1418678A CN 02153312 CN02153312 CN 02153312 CN 02153312 A CN02153312 A CN 02153312A CN 1418678 A CN1418678 A CN 1418678A
- Authority
- CN
- China
- Prior art keywords
- injection
- filters
- filtrate
- radix salviae
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 15
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 13
- 229940079593 drug Drugs 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 108
- 239000000706 filtrate Substances 0.000 claims description 60
- 239000012528 membrane Substances 0.000 claims description 44
- 238000002347 injection Methods 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 42
- 238000004321 preservation Methods 0.000 claims description 36
- 241000628997 Flos Species 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 29
- 230000002879 macerating effect Effects 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 230000006837 decompression Effects 0.000 claims description 24
- 230000014759 maintenance of location Effects 0.000 claims description 24
- 238000004064 recycling Methods 0.000 claims description 24
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 241001072909 Salvia Species 0.000 claims description 13
- 235000017276 Salvia Nutrition 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000000703 high-speed centrifugation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000003643 water by type Substances 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 12
- 239000000890 drug combination Substances 0.000 claims 4
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 abstract 1
- 241000208809 Carthamus Species 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153312 CN1232273C (zh) | 2002-11-27 | 2002-11-27 | 一种治疗心脑血管疾病的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153312 CN1232273C (zh) | 2002-11-27 | 2002-11-27 | 一种治疗心脑血管疾病的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1418678A true CN1418678A (zh) | 2003-05-21 |
CN1232273C CN1232273C (zh) | 2005-12-21 |
Family
ID=4752221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02153312 Expired - Lifetime CN1232273C (zh) | 2002-11-27 | 2002-11-27 | 一种治疗心脑血管疾病的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1232273C (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326520C (zh) * | 2003-08-28 | 2007-07-18 | 北京贤达通科技有限公司 | 一种药物组合物及其在制备治疗或预防心脑血管疾病的药物中的应用 |
CN100382784C (zh) * | 2005-04-11 | 2008-04-23 | 北京正大绿洲医药科技有限公司 | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 |
CN100386094C (zh) * | 2005-01-25 | 2008-05-07 | 咸阳步长医药科技发展有限公司 | 一种治疗心脑血管疾病的口服药物及其制法 |
CN100431562C (zh) * | 2004-02-20 | 2008-11-12 | 于文勇 | 治疗心脑血管疾病的中药丹红制剂及其制备方法 |
CN100446771C (zh) * | 2005-08-18 | 2008-12-31 | 山东轩竹医药科技有限公司 | 一种药用组合物 |
CN100455302C (zh) * | 2004-11-23 | 2009-01-28 | 郭爱华 | 一种治疗心脑血管注射用丹红冻干粉针剂及制备方法 |
CN101002828B (zh) * | 2007-01-10 | 2010-11-03 | 厦门国宇知识产权研究有限公司 | 一种丹红注射液的制备方法及其产品 |
CN101129463B (zh) * | 2007-08-20 | 2011-09-14 | 正大青春宝药业有限公司 | 一种丹参注射液的制备方法 |
CN103142725A (zh) * | 2013-04-08 | 2013-06-12 | 湖南今珠生物科技有限公司 | 一种珍珠丹玫保健制剂 |
CN104257873A (zh) * | 2014-09-04 | 2015-01-07 | 马义磊 | 一种中药麻醉剂及其制备方法 |
CN105920096A (zh) * | 2016-06-12 | 2016-09-07 | 南京中医药大学 | 丹参和红花组合物及其制备方法与应用 |
CN107441163A (zh) * | 2017-08-04 | 2017-12-08 | 上海华源安徽锦辉制药有限公司 | 一种提高丹参滴液稳定性的制备方法 |
-
2002
- 2002-11-27 CN CN 02153312 patent/CN1232273C/zh not_active Expired - Lifetime
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326520C (zh) * | 2003-08-28 | 2007-07-18 | 北京贤达通科技有限公司 | 一种药物组合物及其在制备治疗或预防心脑血管疾病的药物中的应用 |
CN100431562C (zh) * | 2004-02-20 | 2008-11-12 | 于文勇 | 治疗心脑血管疾病的中药丹红制剂及其制备方法 |
CN100455302C (zh) * | 2004-11-23 | 2009-01-28 | 郭爱华 | 一种治疗心脑血管注射用丹红冻干粉针剂及制备方法 |
CN100386094C (zh) * | 2005-01-25 | 2008-05-07 | 咸阳步长医药科技发展有限公司 | 一种治疗心脑血管疾病的口服药物及其制法 |
CN100382784C (zh) * | 2005-04-11 | 2008-04-23 | 北京正大绿洲医药科技有限公司 | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 |
CN100446771C (zh) * | 2005-08-18 | 2008-12-31 | 山东轩竹医药科技有限公司 | 一种药用组合物 |
CN101002828B (zh) * | 2007-01-10 | 2010-11-03 | 厦门国宇知识产权研究有限公司 | 一种丹红注射液的制备方法及其产品 |
CN101129463B (zh) * | 2007-08-20 | 2011-09-14 | 正大青春宝药业有限公司 | 一种丹参注射液的制备方法 |
CN103142725A (zh) * | 2013-04-08 | 2013-06-12 | 湖南今珠生物科技有限公司 | 一种珍珠丹玫保健制剂 |
CN103142725B (zh) * | 2013-04-08 | 2014-09-10 | 湖南今珠生物科技有限公司 | 一种珍珠丹玫保健制剂 |
CN104257873A (zh) * | 2014-09-04 | 2015-01-07 | 马义磊 | 一种中药麻醉剂及其制备方法 |
CN104257873B (zh) * | 2014-09-04 | 2018-08-14 | 马义磊 | 一种中药麻醉剂及其制备方法 |
CN105920096A (zh) * | 2016-06-12 | 2016-09-07 | 南京中医药大学 | 丹参和红花组合物及其制备方法与应用 |
CN105920096B (zh) * | 2016-06-12 | 2020-05-08 | 南京中医药大学 | 丹参和红花组合物及其制备方法与应用 |
CN107441163A (zh) * | 2017-08-04 | 2017-12-08 | 上海华源安徽锦辉制药有限公司 | 一种提高丹参滴液稳定性的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1232273C (zh) | 2005-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1232273C (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN102030834B (zh) | 从茶花中提取制备茶花多糖的方法及所得茶花多糖的用途 | |
CN101085012B (zh) | 一种含红花治疗心血管疾病的组合物及其制剂 | |
KR20000053988A (ko) | 구성약제의 골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법 | |
US20080138445A1 (en) | Pharmaceutical mixture for Hepatitis treatment and its preparation method | |
CN108686113A (zh) | 一种缓解三高症状的组合物及其制备方法 | |
CN102423328B (zh) | 一种治疗脑中风的中药组合物及其制备方法 | |
CN1250253C (zh) | 治疗缺血性脑中风的中药胶囊的制备方法 | |
US20100173028A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
CN1559564A (zh) | 益气复脉制剂及其制备方法 | |
CN105796625A (zh) | 含红曲红花的药物组合物及其制剂 | |
CN1332688C (zh) | 一种治疗血管性痴呆的药物及其制备方法 | |
CN108452073B (zh) | 一种复合植物凝集素及其制备方法和用途 | |
CN100589831C (zh) | 大川芎干粉制剂的制备方法 | |
CN1686451A (zh) | 养心定悸颗粒及其制备方法 | |
CN102670956A (zh) | 一种中药组合物在制备抗心肌细胞凋亡和/或抗心肌细胞凋亡相关疾病的药物中的应用 | |
Cui et al. | Antitumor and immunoregulation effects and mechanism of n-butanol fraction from Zanthoxylum avicennae in H22 mice | |
CN1857706A (zh) | 一点红总黄酮及其药物组合物生产方法 | |
CN1559523A (zh) | 脑得生软胶囊及其制备方法 | |
CN1039784C (zh) | 一种治疗高血压病的中成药 | |
CN1644203A (zh) | 红景天多糖现代复方口服制剂及制备方法 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
CN101167924B (zh) | 一种中药六味地黄制剂的生产方法 | |
JP3382623B2 (ja) | 血管弛緩剤の組成物 | |
CN107213254A (zh) | 复方血栓通制剂在制备治疗paf介导疾病药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BUCHANG MEDICAL SCIENCE & TECHNOLOGY DEVELOPING C Free format text: FORMER OWNER: YU WENYONG Effective date: 20050218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050218 Address after: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Applicant after: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. Address before: 100101 Beijing Chaoyang District Andingmen Camp Road No. 11, room 1012, 1011 Applicant before: Yu Wenyong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEZE BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIANYANG BUCHANG MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20100609 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 20/F, NANYANGGUOJI BUILDING, NO.50, GAOXIN ROAD, NEW+HIGH-TECH WEST ZONE, XI'AN CITY, SHANXI PROVINCE TO: 274000 NO.99, KUNMING ROAD, MUDAN INDUSTRY PARK, HEZE CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100609 Address after: 274000 No. 99, Kunming Road, Heze peony Industrial Park Patentee after: HEZE BUCHANG PHARMACEUTICAL Co.,Ltd. Address before: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee before: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: BUCHANG MEDICAL + DRUG SCIENCE + TECH. DEVELOPMENT Free format text: FORMER OWNER: HEZE BUCHANG PHARMACEUTICAL CO., LTD. Effective date: 20101021 Owner name: HEZE BUCHANG PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: BUCHANG MEDICAL + DRUG SCIENCE + TECH. DEVELOPMENT Free format text: FORMER NAME: HEZE BUCHANG PHARMACEUTICAL CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 274000 NO.99, KUNMING ROAD, MUDAN INDUSTRIAL PARK, HEZE TO: 710075 20/F, NANYANG INTERNATIONAL BUILDING, NO.50, GAOXIN ROAD, W. ZONE OF NEW AND HIGH TECHNOLOGY DEVELOPMENT AREA, XI'AN CITY, SHAANXI PROVINCE |
|
CP03 | Change of name, title or address |
Address after: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Co-patentee after: HEZE BUCHANG PHARMACEUTICAL Co.,Ltd. Patentee after: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. Address before: 274000 No. 99, Kunming Road, Heze peony Industrial Park Patentee before: Heze Buchang Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101021 Address after: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Co-patentee after: HEZE BUCHANG PHARMACEUTICAL Co.,Ltd. Patentee after: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. Address before: 274000 No. 99, Kunming Road, Heze peony Industrial Park Patentee before: Heze Buchang Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: HEZE BUCHANG PHARMACEUTICAL CO., LTD. Owner name: HEZE BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BUCHANG MEDICAL + DRUG SCIENCE + TECH. DEVELOPMENT CO., LTD., XIANYANG Effective date: 20111122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 XI'AN, SHAANXI PROVINCE TO: 274000 KUNMING, YUNNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111122 Address after: 274000 No. 99, Kunming Road, Heze peony Industrial Park Patentee after: HEZE BUCHANG PHARMACEUTICAL Co.,Ltd. Address before: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Co-patentee before: Heze Buchang Pharmaceutical Co.,Ltd. Patentee before: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: SHANDONG DANHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HEZE BUCHANG PHARMA CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 274000 No. 99, Kunming Road, peony Industrial Park, Shandong, Heze Patentee after: Shandong Danhong Pharmaceutical Co.,Ltd. Address before: 274000 No. 99, Kunming Road, peony Industrial Park, Shandong, Heze Patentee before: Heze Buchang Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20051221 |
|
CX01 | Expiry of patent term |